Skip to main content
SpringerLink
Log in

Antikoagulanzien in der Thromboembolieprophylaxe bei Malignomen

  • Conference paper
Malignome und Hämostase

  • 22 Accesses

Zusammenfassung

Die Thromboembolie als paraneoplastisches Syndrom wird wesentlich durch “tissue factor activity” und ein Vitamin-K-abhängiges CancerProkoagulant aus Tumorzellen und Monozyten vermittelt. Die disseminierte intravasale Gerinnung stellt eine klinisch latente oder manifeste Vorstufe der ablaufenden Hyperkoagulabilität dar. Die Diagnostik ist mit modernen gerinnungsanalytischen Verfahren möglich. Therapeutisch ist bisher eine Verbesserung der Überlebenszeit mit oralen Antikoagulanzien nur bei kleinzelligem Bronchialkarzinom belegt. Heparin und niedermolekulare Heparine stellen eine weitere Behandlungsform dar. Besonders die Freisetzung von Tissue-factor-pathway-Inhibitor, die bei niedermolekularen Heparinen nach subkutaner Verabreichung verstärkt erfolgt, könnte als ein weiteres kausales Therapiekonzept bei Malignomen Bedeutung erlangen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ambrus JL, Ambrus CM, Mink IB, Pickren JW (1975) Causes of death in cancer patients. J Med 6: 61–64

    PubMed  CAS  Google Scholar 

  • Bell WR, Starksen NF, Portefield JK (1985) Trousseau’s syndrome: devastating coagulopathy in the absence of heparin. Am J Med 79: 423–430

    Article  PubMed  CAS  Google Scholar 

  • Brown JM (1973) A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res 33: 1217–1224

    PubMed  CAS  Google Scholar 

  • Clarke-Pearson DL, DeLong E, Synan I, Soper JT, Creasman WT, Coleman E (1990) A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 75: 684–689

    Google Scholar 

  • Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR (1990) Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 89: 25–38

    Article  PubMed  CAS  Google Scholar 

  • Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719–725

    Article  PubMed  CAS  Google Scholar 

  • Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, Wiesel ML, Kher A, Barbier P, Cazenave JP (1988) Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 18: 561–567

    Google Scholar 

  • Harenberg J, Baumgärtner A, Fritze D, Zimmermann R (1982) Hypercoagulability after immun-therapy with corynebacterium parvum in man. Blut 44: 241–247

    Article  PubMed  CAS  Google Scholar 

  • Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL (1992) Heparin study in internal medicine (HESIM): design and preliminary results. Thromb Res 68: 33–43

    Article  PubMed  CAS  Google Scholar 

  • Hilgard P, Maat B (1979) Mechanism of lung tumor colony reduction caused by coumarin anticoagulation. Eur J Cancer 15: 183–187

    Article  PubMed  CAS  Google Scholar 

  • Hilgard P, Schulte H, Wetzig G, Schmitt G, Schmidt CG (1977) Oral anticoagulation in the treatment of a spontaneously metastasising murine tumor (3LL). Br J Cancer 35: 78–85

    Article  PubMed  CAS  Google Scholar 

  • Hilgard P (1977) Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer 35: 891–892

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Levine MN (1992) Low-molecular-weight heparin. Blood 79: 1–17

    PubMed  CAS  Google Scholar 

  • Hoerr SO, Harper JR (1957) On peripheral thrombophlebities–Its occurrence as a presenting symptom of malignant disease of pancreas, biliary tract, or duodenum. JAMA 164: 2033–2044

    CAS  Google Scholar 

  • Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S (1993) Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341: 259–265

    Article  PubMed  CAS  Google Scholar 

  • Kasimis BS, Spiers AD (1979) Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 159: 83–85

    Google Scholar 

  • Kazmler FJ, Bowle EJW, Hagedorn AB, Owen CA (1974) Treatment of intravascular coagulation and fibrinolysis ( ICF) syndrom. Mayo Clin Proc 49: 665–672

    Google Scholar 

  • Kirsch WM, Schulz D, Buskirk JJ van, Young HE (1974) Effects of sodium warfarin and other carcinostatic agents on malignant cells: A study of drug synergy. J Med 5: 69–82

    Google Scholar 

  • Lieberman JS, Borrero J, Urdanetta E, Wright IS (1961) Thrombophlebitis and cancer. JAMA 177: 542–545

    PubMed  CAS  Google Scholar 

  • Maat B (1980) Selective macrophage inhibition abolishes warfarin-induced reduction of metastases. Br J Cancer 41: 313–316

    Article  PubMed  CAS  Google Scholar 

  • Myers TJ, Rickles FR, Barb C, Cronlund M (1981) Activation of blood coagulation in acute leukemiafibrinopeptide A ( FPA) generation as an indicator of disease activity. Blood 57: 518–525

    Google Scholar 

  • Owen CA Jr, Bowie EJW (1974) Chronic intravascular coagulation syndromes, a summary. Mayo Clin Proc 49: 673–679

    PubMed  Google Scholar 

  • Peuscher FW, Cleton FJ, Armstrong L, Stoepman val Dalen EA, Mourik JA van, Aken WG van (1980) Significance of plasma fibrinopeptide A ( FPA) in patients with malignancy. J Lab Clin Med 96: 5–14

    Google Scholar 

  • Pineo GF, Brain MC, Galkes AS, Hirsh J, Hatton MWC, Regoeczi E (1974) Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 230: 262–270

    Article  PubMed  CAS  Google Scholar 

  • Poggi A, Mussoni L, Kornblihtt L, Ballabio E, de Gaetano G, Donati MB (1978) Warfarin enantiomers, anticoagulation and experimental tumor metastasis. Lancet s: 163–164

    Google Scholar 

  • Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62: 14–31

    Google Scholar 

  • Rickles FR, Edwards RL, Barb C, Cronlund M (1983) Abnormalities of blood coagulation in patients with cancer. Cancer 51: 301–307

    Article  PubMed  CAS  Google Scholar 

  • Rubin RN, Colman RW (1992) Disseminated intravascular coagulation approach to treatment. Drugs 44: 963–971

    Article  PubMed  CAS  Google Scholar 

  • Sack GH ir, Leven J, Bell WR (1977) Trousseau’s syndrome and other manifesations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56: 1–37

    Google Scholar 

  • Soong BCR, Miller SO (1970) Coagulation disorders in cancer. III. Fibrinolysis and inhibitors. Cancer 25: 867–873

    Google Scholar 

  • Sproule EE (1938) Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34: 566–585

    Google Scholar 

  • Strauss JF, Saphir O (1949) The possible significance of altered blood coagulability on the spread of carcinoma cells. Proc Inst Med Chic 17: 263

    Google Scholar 

  • Sunder-Plassman G, Speiser W, Korninger C, Stain M, Bettelheim P et al. (1991) Disseminated intravascular coagulation and decrease in fibrinogen levels induced by vincristine/predni-solone therapy of lymphoid blast crisis of chronic myeloid leukemia. Ann Hematol 62: 169–173

    Article  Google Scholar 

  • Thornes RD, Edlow DW, Wood S (1968) Inhibition of locomotion of cancer cells in vivo by anticoagulant therapy-1. Effects of sodium warfarin on V2 cancer cells, granulocytes, lymphocytes, and macrophages in rabbits. Johns Hopkins Med J 123: 305–316

    PubMed  CAS  Google Scholar 

  • Trousseau A (1965) Phlegmasia alba dolens. Clinique Medicale de l’Hotel-Dieu de Paris, London, New Sydenham Society 3: 94

    Google Scholar 

  • Yoda Y, Abe T (1981) Fibrinopeptide A ( FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemostas 46: 706–709

    Google Scholar 

  • Yudelman J, Greenberg J (1982) Factors affecting fibrinopeptide A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 59: 787–792

    PubMed  CAS  Google Scholar 

  • Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim S-H, O’Donnell JF, Dell R, Tornyos K, Kwann HC (1984) Effect of warfarin anticoagulant on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 53: 2046–2052

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Harenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Boehringer Mannheim, Sandhofer Str. 116, 68305, Mannheim, Deutschland

    Eberhard Spanuth

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Harenberg, J. (1996). Antikoagulanzien in der Thromboembolieprophylaxe bei Malignomen. In: Spanuth, E. (eds) Malignome und Hämostase. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79744-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79744-6_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-59253-2

  • Online ISBN: 978-3-642-79744-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation